Biomerica stock: buy or sell?

BMRA stock price: $7.15 -0.69% At close on March 31st, 2020

Updated on:
March 31st, 2020

3

Biomerica ended today at $7.15 and depreciated a lame -0.69%. On Thursday BMRA collapsed a hair-raising -5.62%. On Friday BMRA climbed an exceptional 5.46%.

Biomerica, Inc., together with its subsidiaries, develops, manufactures, and markets medical diagnostic products for the early detection and monitoring of chronic diseases and medical conditions worldwide.

Should I buy Biomerica stock?

Trading stocks requires experience and discipline, and your buying and selling decisions must come following a methodology. Following a trading plan helps to make decisions easier, quicker and with less hesitations. There are thousands of trading strategies for you to choose, but at Stocks2.com we prefer those that are simple but successful.

Currently, Biomerica stock doesn't match any of these trading strategies, so our recommendation is not to buy.

Buy setupElegible
New all-time highNo
New 52 week highNo
Price crossing up 200d MANo
100d MA crossing up 200d MANo
This is not a selling recommendation at all, just it's not the best moment to buy if you follow any of these trading strategies.

Is Biomerica stock a buy?

Everyday, hundreds of stock ratings are published by financial analysts to indicate a particular stock's attractiveness. Unfortunately, we couldn't find any rating for BMRA stock for the last month.

Biomerica stock analysis

Daily outlook

Biomerica depreciated a lame -0.69% and closed at $7.15.

On March 19th, BMRA hit a new all time high, pushing higher than tops. Check different trading setups that use ATHs as triggers. Biomerica depreciated a lame -0.69% and closed at $7.15. Since price and SMA200d lines crossed up on March 18th, BMRA climbed $4.78 (201.69%). On March 18th, SMA50d and SMA100d crossed up triggering a rise of 201.69%.

BMRA stock chart (daily)

Weekly outlook

Shares of Biomerica rose a beatiful 2.73% this week. By mid March BMRA rocketed an extraordinary 64.34% in just one week. Early March BMRA plunged a frightening -27.06% in just one week.

Not so far away is the last all-time high Biomerica marked by mid March, but since then it dropped a 69.43%. Biomerica stock is drawing an uptrend with rising tops and bottoms. Now trading in between its last bottom and last top, BMRA might consolidate in a flat-base, waiting to break out over or down under . By mid March, SMA20w and SMA40w crossed up triggering a rise of 180.39%. Since mid March when BMRA stock price broke up the SMA40w line, it gained $4.60 (180.39%).

BMRA stock chart (weekly)

Biomerica stock price history

Biomerica stock went public on September 7th, 1984 with a price of $5.501. Since then, BMRA stock surged a 30.00%, with an average of 0.90% per year. If you had invested right after BMRA's IPO a $1,000 in Biomerica stock in 1984, it would worth $300.00 today.

1: Adjusted price after possible price splits or reverse-splits.

Biomerica stock historical price chart

BMRA stock reached all-time highs on March 19th with a price of $23.39.

Biomerica stock price target

Nobody can reliably foresee how stock prices may evolve in the future. However, financial institutions invest time and resources to provide the most accurated estimations to help investors to make their decisions. We do not recommend to follow these stock price predictions without a critical thinking from your side, as their accuracy is usually low. For the last month we have not detected any price prediction for Biomerica stock by any trusted analyst.

Financials and fundamental analysis

Earnings date and Earnings per Share

After publishing its last earnings report on April, Biomerica . As soon as we get its posted EPS from the earnings report, we will extend this review.
BMRA earnings date and EPS evolution
QuarterReporting dateEstimated EPSActual EPSSurprise
2017-Q2-n/a-0.04n/a
2017-Q3-n/a-0.02n/a
2017-Q4-n/a-0.03n/a
2018-Q12018-04-16-0.06-0.04n/a
2018-Q22018-08-30-0.06-0.08n/a
2018-Q32018-10-16-0.06-0.05n/a
2018-Q42019-01-15-0.06-0.05n/a
2019-Q12019-04-15-0.05n/an/a
2019-Q2-n/an/an/a
2019-Q3-n/an/an/a

Annual financial results

Compared to 2017, last anual sales report draw a fatal drop down of -3.93% to $5.56 M dollars. When comparing 2018 vs 2017, slightly worse, profit margin (that is, the net income divided by revenues) plummed a -10.66% to -26.34%.

Biomerica presents anual results in May, and to evaluate its evolution since then, we estimate annual sales and income figures by adding results from the last 4 quarters. This is called TTM (or Twelve Trailing Months). So, Biomerica TTM sales up to February 2019 were $5.17 and earnings $-2.28 million dollars. If we compare this TTM figures with the last reported annuality, we can esteem Biomerica business evolution since May 2018: Annual turnover up to February, compared to lastest yearly report, slipped a rough -7.17%. On the other hand, profit margin (net income/sales) plunged at -26.34%.

BMRA annual Sales and Income evolution
YearSalesYoYIncome/(margin)YoY
2013$6.47 M-$0.54 M8.3%-
2014$5.12 M-20.87%$-0.22 M-4.2%-140.16%
2015$4.96 M-3.08%$-0.33 M-6.7%53.67%
2016$5.14 M3.58%$-1.50 M-29.2%352.55%
2017$5.79 M12.68%$-0.91 M-15.7%-39.42%
2018$5.56 M-3.93%$-1.47 M-26.3%61.34%
TTM $5.17 M-7.17%$-2.28 M-44.1%55.23%

Quarterly financial results

Biomerica reported $1.26 million in revenues for 2019-Q1, a -15.97% decline compared to previous quarter. Reported quarter earnings marked $-0.68 million with a profit margin of -53.82%. Profit margin plunged a -22.02% compared to previous quarter when profit margin was -31.80%. When comparing sales to same quarter last year, Biomerica sales marked a shocking correction and fell a -8.32%.
BMRA quarterly Sales and Income evolution
QuarterSales1QoQ2Income1/(margin)QoQ2
2017-Q2$1.45 M-$-0.35 M-23.8%-
2017-Q3$1.44 M-0.69%$-0.21 M-14.4%-40.13%
2017-Q4$1.61 M12.06%$-0.27 M-16.6%29.75%
2018-Q1$1.38 M-14.75%$-0.32 M-23.4%20.04%
2018-Q2$1.13 M-17.83%$-0.67 M-59.1%107.02%
2018-Q3$1.27 M12.60%$-0.45 M-35.5%-32.34%
2018-Q4$1.50 M17.91%$-0.48 M-31.8%5.65%
2019-Q1$1.26 M-15.97%$-0.68 M-53.8%42.22%

Biomerica ownership

When you are planning to buy shares of a stock, it's worth to review its ownership structure.

Biomerica shares owned by insiders (that is, founders, CEO, CTO, main executives or other management staff) currently counts a 21.07% of all shares.

In case of Biomerica stock, 8.04% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for BMRA stock account 0.00%, no big difference from last month.

The following table compares ownership indicators for other stocks related to Biomerica:

BMRA
Market cap$70.7 M
Total shares9.9 M
Float shares7.7 M
  - Institutional holdings (%)8.0%
  - Insider holdings (%)21.1%
Shares in short selling0.0%

Biomerica summary

Tuesday, March 31st, 2020
Open$7.20
Close$7.15
Day range$6.75 - $7.30
Previous close$7.20
Session gain-0.69%
Average true range$3.15
50d mov avg$4.02
100d mov avg$3.47
200d mov avg$3.23
Daily pattern
Weekly pattern lt06a

Biomerica performance

To measure stock performance is always good to benchmark with competitors or related stocks. We chose as the bechmarking frame for Biomerica stock.
Stock3m6m12m
BMRABiomerica154.45%123.44%184.86%

Biomerica competitors

Unfortunately, we could not find any public company that could be defined as Biomerica competitor. This doesn't mean Biomerica does not have any competitor in the market, it's just we could not detected it.